The event will see speakers from Novartis, Cytiva, GSK, Roche, AstraZeneca, Janssen, BioMax, Ionis, Biogen and Sixfold converge at the Novartis campus in Basel for two days, from Tuesday 28th to Wednesday 29th of March, 2023.

Sixfold Bioscience founder and co-CEO Dr. Perdrix Rosell will be presenting her talk on “‘RNA to deliver RNA’ – programmable delivery systems for targeted non-hepatic delivery” at 14:45 pm CET on Tuesday 28th.

This years’ theme is "Continuing Excellence in Oligo Development - Maximizing Healthcare Benefits" and will feature talks on:

• Review of the last 10 years, and looking forward to the next
• Manufacturing Technologies
• Analysing oligos
• Alternative drug delivery mechanisms
• Patient perspective

Sixfold Bioscience is a venture-backed preclinical-stage biotechnology company, founded in 2017, based at the Translation & Innovation Hub in White City, London. Sixfold develops programmable drug delivery systems, with a current focus on siRNA and ASO.

Sixfold’s RNA delivery platform, Mergo®, was conceived by co-founders Dr Perdrix Rosell and Dr George Foot, who were left frustrated by current delivery systems that were either too toxic or faced complex engineering challenges. The Company’s differentiated approach is based on engineering biocompatible nano-architectures with precise chemical profiles that guide the RNA to selected organs.